Who we are:

Plasma Screening Experts

Who we are:

Plasma Screening Experts

NGI is focused on providing high-quality donor qualification and source plasma donation screening services to the global plasma industry.  We are an established leader in the field of nucleic acid screening services and are currently expanding our offerings to provide full-service donor screening support including viral marker testing (VMT) and ancillary testing services.  We screen millions of plasma donations a year for infectious agents and have optimized our processes to ensure exceptional turn-around times (TAT). The company also has provided numerous innovative laboratory solutions to pharmaceutical and biotechnology companies.  Examples include the development, installation, maintenance, and staffing of large scale laboratory robotic automation solutions (see www.Protedyne.com) and development, maintenance, and staffing of laboratory information management system (LIMS)  applications and architecture, to support comprehensive donor screening of millions of donor samples per year.  By leveraging the purchasing power of our parent company, LabCorp®, we provide our clients with industry-leading testing services and cost efficient solutions for donor plasma analysis.

NGI is licensed as a clinical laboratory provider by both state and federal agencies, participates in a number of approved quality control programs, and holds active Biologics Licenses from the US Food and Drug Administration (FDA) for screening of plasma for blood borne infectious agents. Our ~63,000 square-foot laboratory facilities are located in Los Angeles within 10 miles of the Los Angeles International (LAX) airport.

Meet Our Team

  • Josh Goldsmith, PhD

    Vice President and General Manager

    Josh Goldsmith is the VP and General Manager of NGI. Josh holds a Ph.D. in chemistry and has been with LabCorp since 2006 working in a variety of roles in translational medicine/biomarkers, sales, marketing, and operations. Prior to joining NGI, Josh supported business development leading global clinical trials commercial team and co-leading the integration of LabCorp Clinical Trials with Covance.

  • Brian Poirier, MD

    Medical Director

    Dr Brian Poirier is a Medical Director with LabCorp and Discipline Director of LabCorp’s Immunohematology Division.  Dr Poirier joined LabCorp in 2014, and has served as Medical Director for both LabCorp regional laboratories as well as Medical Director of LabCorp’s Colorado Coagulation laboratory.  Prior to joining LabCorp, Dr Poirier served as Medical Director at Creative Testing Solutions and Blood Systems, Inc, as well as covering hospital transfusion services at both Mayo Hospital, Phoenix and Banner MD Anderson hospital, Phoenix. 

  • Jeff Albrecht, PhD

    Director of Research and Development

    Dr Albrecht obtained his Bachelor of Science degree in Microbiology from the University of Illinois Urbana-Champaign in 1989 and his Ph.D. degree in Microbiology and Molecular Genetics from the University of California at Los Angeles (UCLA) in 1996. During his graduate studies and post-doctoral fellowship in the Microbiology and Molecular Genetics department at UCLA, Dr Albrecht investigated the anaerobic regulation of cytochrome o and cytochrome d oxidase operons in Escherichia coli. Dr Albrecht joined National Genetics Institute in 1996 as the Director of Research and Development. Under his leadership, National Genetics Institute has developed PCR assays for the detection of melanoma cells in blood and lymph nodes, Human Papiloma virus from cervical swabs, and Epstein-Barr virus in plasma and peripheral blood leukocytes as well as nucleic acid testing assays for West Nile Virus, Simian Virus, and Poliovirus. With his guidance, National Genetics has also refined testing procedures and optimized the sensitivity and efficiency of existing Hepatitis A, B, C and HIV assays.

  • Louis Leano

    Operations Manager

    Louis Leano is an Operations Manager at NGI. Louis is responsible for the source plasma screening business at NGI. Louis has 20+ years of experience in the source plasma screening industry. Mr. Leano holds a Bachelor of Science degree in biology from the University of California, Los Angeles. Louis is committed to providing NGI clients with exceptional customer service and ensuring rapid turn-around times.

  • Geri Cox, CLS

    Director of Regulatory Affairs / Quality Systems

    Geri Cox joined NGI prior to the LabCorp acquisition over 20 years ago. As a California licensed CLS, Geri’s experience includes both technical and quality assurance in hospital, reference, and donor center laboratory environments.  Geri developed NGI’s quality system and managed regulatory matters when she was not working “at the bench” in the viral culture laboratory.  As NGI grew and obtained FDA licenses for three laboratory developed assays, Geri’s primary focus became regulatory affairs. She led NGI through development of CLIA and FDA quality standards and continues to be responsible for regulatory affairs and managing NGI’s quality system.

  • Lora Turovsky, CLS

    Laboratory Manager, Serology

    Lora Turovsky joined NGI in 2018 to lead the expansion of the site’s VMT efforts.  Lora is Laboratory Manager with responsibility over Donor Screening Laboratory operations. Lora holds a MS in Health Administration, and a degree in Biology/Biochemistry with additional coursework in medical technology and a Clinical Laboratory Science (CLS) license from the California State Department of Health. Lora has more than 20 years of combined laboratory and quality systems experience, and an in-depth knowledge in infectious disease testing. 
     

  • Bryce Chaney

    Business Development Executive

    Bryce Chaney joined the NGI team in 2018 to lead the business development, sales and marketing efforts.  Mr. Chaney received his Bachelor of Science degree in Biochemistry from UNC Charlotte and his MBA from UNC Chapel Hill Kenan-Flagler Business School.  Prior to joining LabCorp, Bryce served in various business development and strategy roles for pharmaceutical service companies including KIYATEC, Patheon (formerly DSM Pharmaceuticals), Aptuit, SCYNEXIS and Cirrus Pharmaceuticals.  Mr. Chaney began his career at BD Technologies (Becton Dickinson’s corporate research laboratories) and worked in the areas of chemical toxicology, stem cell technologies and laboratory automation.  Bryce is an advisor to UNC Chapel Hill’s New Venture Launch Courses, an Adams Apprentice at UNC Chapel Hill, and a board member of Plakous Therapeutics, True Justice International and DEC Labs.